Chief Executive Officer Belén Garijo used the company’s presentation at the 44th J.P. Morgan Healthcare Conference to outline ...

UK regulators have approved nirogacestat as the first licensed drug for adults with progressive desmoid tumours.

The Cambridge, Massachusetts-based company – known as FogPharma until a rebrand in 2024 – needs cash for pivotal trials of ...

Nirogacestat therapy shows sustained benefits, including tumor shrinkage and durable responses, in long-term treatment of desmoid tumors. DeFi trial results show that continuous nirogacestat provides ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...

Elevated M&A volume activity continued in the third quarter with $1.3 trillion in announced transactions. Technology and financials continued to be the top sectors for M&A. The regulatory environment ...

Looking comfortable in a kurta, Belen Garijo, Chair–Executive Board and Chief Executive Officer of the German Science and ...

Researchers at the University of Michigan have identified a novel way to counter drug resistance in KRAS-mutant non-small ...

The layoffs come after a life sciences company was taken private last year by a German pharma giant.

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.